iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC lifted its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 3.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 640,350 shares of the company’s stock after buying an additional 20,092 shares during the period. Geode Capital Management LLC owned approximately 1.75% of iTeos Therapeutics worth $6,540,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. State Street Corp boosted its position in iTeos Therapeutics by 21.9% during the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company’s stock worth $12,000,000 after acquiring an additional 211,452 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of iTeos Therapeutics by 14.8% during the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock valued at $13,481,000 after purchasing an additional 117,159 shares in the last quarter. Candriam S.C.A. acquired a new stake in iTeos Therapeutics in the second quarter worth about $7,558,000. Algert Global LLC grew its position in iTeos Therapeutics by 92.0% in the 3rd quarter. Algert Global LLC now owns 256,139 shares of the company’s stock valued at $2,615,000 after buying an additional 122,730 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in iTeos Therapeutics by 3.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 222,135 shares of the company’s stock valued at $2,268,000 after buying an additional 8,397 shares during the period. 97.16% of the stock is owned by institutional investors.

Insider Transactions at iTeos Therapeutics

In other news, CFO Matthew Gall acquired 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average price of $7.73 per share, with a total value of $38,650.00. Following the purchase, the chief financial officer now owns 65,429 shares of the company’s stock, valued at approximately $505,766.17. This trade represents a 8.27 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 12.50% of the stock is currently owned by insiders.

iTeos Therapeutics Stock Performance

Shares of NASDAQ:ITOS opened at $8.15 on Friday. The stock has a market capitalization of $297.75 million, a price-to-earnings ratio of -2.59 and a beta of 1.37. iTeos Therapeutics, Inc. has a 1-year low of $7.09 and a 1-year high of $18.75. The company has a 50 day moving average price of $8.21 and a 200 day moving average price of $12.03.

iTeos Therapeutics (NASDAQ:ITOS) last issued its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. On average, sell-side analysts expect that iTeos Therapeutics, Inc. will post -3.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ITOS. Wells Fargo & Company dropped their target price on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Wedbush reissued an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research note on Thursday, December 12th. Finally, HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of iTeos Therapeutics in a report on Friday, December 13th.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.